P/E Ratio

The P/E ratio of 43.3x means investors are currently paying $43.30 for every $1 of Revvity’s earnings per share — a measure of how expensive the stock is relative to its profitability.

This is well above the Healthcare sector median of 27.0x, placing the company in the 85th percentile among its peers, indicating a premium valuation. No trend data is available because the year-over-year change and quarter-over-quarter change are both listed as N/A, and the historical values consist of only the current figure. The combination of a high P/E level with no trend information creates uncertainty: the stock may be priced for above-average growth, but without a direction, an investor cannot assess whether the premium is expanding or contracting. This lack of trend data introduces additional risk, as any slowdown in earnings could make the current multiple unsustainable. The elevated P/E does not directly contradict the overall NEUTRAL verdict, but it supports a cautious stance by warning that the company must deliver strong earnings growth to justify its relative cost.

Frequently Asked Questions

Closest Sector Peers